Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go wearable insulin delivery device in Australia and New Zealand.
According to the terms of the agreement, AMSL Diabetes and NZMS Diabetes retain the right to promote, market and sell the V-Go device to clinics and patients, while Valeritas remains responsible for regulatory and manufacturing activities. Financial terms of the deal were not disclosed.
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.